Advaxis Inc. (NASDAQ:ADXS) shares were up 4.8% on Monday . The stock traded as high as $14.51 and last traded at $14.36, with a volume of 801,585 shares traded. The stock had previously closed at $13.70.

Several research analysts have recently weighed in on ADXS shares. FBR & Co reaffirmed an “outperform” rating and set a $34.00 target price on shares of Advaxis in a research note on Tuesday, May 17th. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a research note on Friday, August 5th. Jefferies Group reissued a “buy” rating on shares of Advaxis in a research note on Thursday, August 4th. Finally, Barclays PLC increased their price objective on Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, August 3rd. Six analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $25.80.

The company’s market capitalization is $460.58 million. The stock’s 50 day moving average is $10.75 and its 200 day moving average is $8.80.

In other news, Director Richard J. Berman sold 18,000 shares of the stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $15.21, for a total transaction of $273,780.00. Following the sale, the director now directly owns 66,430 shares in the company, valued at approximately $1,010,400.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David Sidransky sold 22,808 shares of the stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $15.01, for a total value of $342,348.08. Following the sale, the director now owns 91,759 shares in the company, valued at $1,377,302.59. The disclosure for this sale can be found here.

Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.